The Experts below are selected from a list of 279 Experts worldwide ranked by ideXlab platform
Panchyr Yang - One of the best experts on this subject based on the ideXlab platform.
-
targeting tumor microenvironment by bioreduction activated nanoparticles for light triggered virotherapy
ACS Nano, 2018Co-Authors: Sja Tseng, Ivan M Kempson, Kuoyen Huang, Zixian Liao, Panchyr YangAbstract:Solid tumors characteristically display higher levels of lactate production due to anaerobic metabolism of glucose. Meanwhile, the U.S. Food and Drug Administration (FDA) has approved virotherapy for use in cancer treatment; however systemic administration remains as a particular challenge. Here we report exploitation of tumor lactate production in designing a hypoxia-responsive carrier, self-assembled from hyaluronic acid (HA) conjugated with 6-(2-nitroimidazole)Hexylamine, for localized release of recombinant adeno-associated virus serotype 2 (AAV2). The carrier is loaded with lactate oxidase (LOX) and is permeable to small molecules such as the lactate that accumulates in the tumor. Subsequently, LOX oxidizes the lactate to pyruvate inside the carrier, accompanied by internal lowering of oxygen partial pressure. Bioreduction of the 2-nitroimidazole of the HA conjugated with 6-(2-nitroimidazole)Hexylamine converts it into a hydrophilic moiety and electrostatically dissociates the carrier and virus. Efficacious and specific delivery was proven by transduction of a photosensitive protein (KillerRed), enabling significant limitation in tumor growth in vivo with photodynamic therapy. An approximate 2.44-fold reduction in tumor weight was achieved after a 2-week course, compared with control groups. Furthermore, conjugation of the AAV2 with iron oxide nanoparticles ("magnetized" AAV2) facilitated magnetic resonance imaging tracking of the virus in vivo. Taken together, the solid tumor microenvironment promotes bioreduction of the lactate-responsive carrier, providing rapid and specific delivery of AAV2 for light-triggered virotherapy via systemic administration.
-
Targeting Tumor Microenvironment by Bioreduction-Activated Nanoparticles for Light-Triggered Virotherapy
2018Co-Authors: Sja Tseng, Ivan M Kempson, Kuoyen Huang, Zixian Liao, Panchyr YangAbstract:Solid tumors characteristically display higher levels of lactate production due to anaerobic metabolism of glucose. Meanwhile, the U.S. Food and Drug Administration (FDA) has approved virotherapy for use in cancer treatment; however systemic administration remains as a particular challenge. Here we report exploitation of tumor lactate production in designing a hypoxia-responsive carrier, self-assembled from hyaluronic acid (HA) conjugated with 6-(2-nitroimidazole)Hexylamine, for localized release of recombinant adeno-associated virus serotype 2 (AAV2). The carrier is loaded with lactate oxidase (LOX) and is permeable to small molecules such as the lactate that accumulates in the tumor. Subsequently, LOX oxidizes the lactate to pyruvate inside the carrier, accompanied by internal lowering of oxygen partial pressure. Bioreduction of the 2-nitroimidazole of the HA conjugated with 6-(2-nitroimidazole)Hexylamine converts it into a hydrophilic moiety and electrostatically dissociates the carrier and virus. Efficacious and specific delivery was proven by transduction of a photosensitive protein (KillerRed), enabling significant limitation in tumor growth in vivo with photodynamic therapy. An approximate 2.44-fold reduction in tumor weight was achieved after a 2-week course, compared with control groups. Furthermore, conjugation of the AAV2 with iron oxide nanoparticles (“magnetized” AAV2) facilitated magnetic resonance imaging tracking of the virus in vivo. Taken together, the solid tumor microenvironment promotes bioreduction of the lactate-responsive carrier, providing rapid and specific delivery of AAV2 for light-triggered virotherapy via systemic administration
A V Nushtaeva - One of the best experts on this subject based on the ideXlab platform.
-
stabilization of water in oil emulsions with complex of silica particles and Hexylamine
Наносистемы: физика химия математика, 2015Co-Authors: A V NushtaevaAbstract:The properties of emulsions stabilized by complexes of silica particles with Hexylamine are analyzed. It is shown that water-in-oil emulsions were obtained only if the Hexylamine volume fraction was greater than that of the silica (Aerosil) volume fraction in the aqueous phase. So, in the case of water-in-oil emulsions, Hexylamine is a completely equivalent co-stabilizer together with silica, rather than just a solid surface modifier. It is assumed that at high concentrations this short-chain surfactant, together with silica, forms hybrid organic-inorganic particles that are attached at the oil/water interface and promotes the formation of oil droplets in the water.
-
contact angles of selective wetting of Hexylamine modified silica surface
Colloids and Surfaces A: Physicochemical and Engineering Aspects, 2014Co-Authors: A V NushtaevaAbstract:Abstract It is shown experimentally that modification of silica particles by short-chain surfactant like Hexylamine leads to inversion of selective wetting angle θ of the particles and to phase inversion in the emulsions stabilized by the Hexylamine-modified silica particles. Empiric diagram of emulsion stability shows that at the contact angle θ close to 90° there is region of completely unstable emulsions between regions of stable emulsions of oil-in-water and water-in-oil types in the case of volume fraction of oil O oil = 0.25 or 0.75. At O oil = 0.5 the emulsion type and stability corresponded to the aqueous phase receding and advancing contact angles.
-
stabilization of emulsions and emulsion films by silica with Hexylamine
Mendeleev Communications, 2012Co-Authors: A V NushtaevaAbstract:The conditions of stabilization of emulsions with silica particles modified by Hexylamine and the thickness of free water-in-oil films have been determined.
Sja Tseng - One of the best experts on this subject based on the ideXlab platform.
-
targeting tumor microenvironment by bioreduction activated nanoparticles for light triggered virotherapy
ACS Nano, 2018Co-Authors: Sja Tseng, Ivan M Kempson, Kuoyen Huang, Zixian Liao, Panchyr YangAbstract:Solid tumors characteristically display higher levels of lactate production due to anaerobic metabolism of glucose. Meanwhile, the U.S. Food and Drug Administration (FDA) has approved virotherapy for use in cancer treatment; however systemic administration remains as a particular challenge. Here we report exploitation of tumor lactate production in designing a hypoxia-responsive carrier, self-assembled from hyaluronic acid (HA) conjugated with 6-(2-nitroimidazole)Hexylamine, for localized release of recombinant adeno-associated virus serotype 2 (AAV2). The carrier is loaded with lactate oxidase (LOX) and is permeable to small molecules such as the lactate that accumulates in the tumor. Subsequently, LOX oxidizes the lactate to pyruvate inside the carrier, accompanied by internal lowering of oxygen partial pressure. Bioreduction of the 2-nitroimidazole of the HA conjugated with 6-(2-nitroimidazole)Hexylamine converts it into a hydrophilic moiety and electrostatically dissociates the carrier and virus. Efficacious and specific delivery was proven by transduction of a photosensitive protein (KillerRed), enabling significant limitation in tumor growth in vivo with photodynamic therapy. An approximate 2.44-fold reduction in tumor weight was achieved after a 2-week course, compared with control groups. Furthermore, conjugation of the AAV2 with iron oxide nanoparticles ("magnetized" AAV2) facilitated magnetic resonance imaging tracking of the virus in vivo. Taken together, the solid tumor microenvironment promotes bioreduction of the lactate-responsive carrier, providing rapid and specific delivery of AAV2 for light-triggered virotherapy via systemic administration.
-
Targeting Tumor Microenvironment by Bioreduction-Activated Nanoparticles for Light-Triggered Virotherapy
2018Co-Authors: Sja Tseng, Ivan M Kempson, Kuoyen Huang, Zixian Liao, Panchyr YangAbstract:Solid tumors characteristically display higher levels of lactate production due to anaerobic metabolism of glucose. Meanwhile, the U.S. Food and Drug Administration (FDA) has approved virotherapy for use in cancer treatment; however systemic administration remains as a particular challenge. Here we report exploitation of tumor lactate production in designing a hypoxia-responsive carrier, self-assembled from hyaluronic acid (HA) conjugated with 6-(2-nitroimidazole)Hexylamine, for localized release of recombinant adeno-associated virus serotype 2 (AAV2). The carrier is loaded with lactate oxidase (LOX) and is permeable to small molecules such as the lactate that accumulates in the tumor. Subsequently, LOX oxidizes the lactate to pyruvate inside the carrier, accompanied by internal lowering of oxygen partial pressure. Bioreduction of the 2-nitroimidazole of the HA conjugated with 6-(2-nitroimidazole)Hexylamine converts it into a hydrophilic moiety and electrostatically dissociates the carrier and virus. Efficacious and specific delivery was proven by transduction of a photosensitive protein (KillerRed), enabling significant limitation in tumor growth in vivo with photodynamic therapy. An approximate 2.44-fold reduction in tumor weight was achieved after a 2-week course, compared with control groups. Furthermore, conjugation of the AAV2 with iron oxide nanoparticles (“magnetized” AAV2) facilitated magnetic resonance imaging tracking of the virus in vivo. Taken together, the solid tumor microenvironment promotes bioreduction of the lactate-responsive carrier, providing rapid and specific delivery of AAV2 for light-triggered virotherapy via systemic administration
Mark P Bowman - One of the best experts on this subject based on the ideXlab platform.
-
nucleophile initiated thiol michael reactions effect of organocatalyst thiol and ene
Macromolecules, 2010Co-Authors: Justin W Chan, Andrew B Lowe, Charles E Hoyle, Mark P BowmanAbstract:A detailed evaluation of the kinetics of the thiol-Michael reaction between hexanethiol and hexyl acrylate is described. It is shown that primary amines are more effective catalysts than either secondary or tertiary amines with, for example, quantitative conversion being achieved within 500 s in the case of Hexylamine with an apparent rate constant of 53.4 mol L−1 s−1 at a catalyst loading of 0.057 mol %. Certain tertiary phosphines, and especially tri-n-propylphosphine and dimethylphenylphosphine, are shown to be even more effective species even at concentrations 2 orders of magnitude lower than employed for Hexylamine and performed in solution with quantitative conversions reached within ca. 100 s for both species and apparent rate constants of 1810 and 431 mol L−1 s−1, respectively. The nature of the thiol is also demonstrated to be an important consideration with mercaptoglycolate and mercaptopropionate esters being significantly more reactive than hexanethiol with reactivity mirroring the pKa of the ...
E. Cano - One of the best experts on this subject based on the ideXlab platform.
-
substitutional inhibition mechanism of mild steel hydrochloric acid corrosion by Hexylamine and dodecylamine
Journal of Applied Electrochemistry, 2000Co-Authors: J. M. Bastidas, J L Polo, E. CanoAbstract:Hexylamine and dodecylamine were investigated as inhibitors of mild steel hydrochloric acid corrosion, in concentrations from 1 × 10−6 to 1.0 M, at a temperature of 298 K. For a given inhibitor concentration, dodecylamine showed higher effectiveness than Hexylamine. The inhibitor mechanism was treated as a substitutional adsorption process according to Flory–Huggins (FH), Dhar–Flory–Huggins (DFH) and Bockris–Swinkels (BS) isotherms. The best approach was obtained using FH and DFH isotherms, with one molecule of inhibitor replacing three molecules of water. A structural parameter, the projected molecular area of these two inhibitors, was calculated to elucidate inhibitor orientation in the adsorption process.